John M. Bedtelyon

Array ( [id] => 10968263 [patent_doc_number] => 20140371296 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-12-18 [patent_title] => 'METHODS FOR MODULATING METASTASIS-ASSOCIATED-IN-LUNG-ADENOCARCINOMA-TRANSCRIPT-1 (MALAT-1) EXPRESSION' [patent_app_type] => utility [patent_app_number] => 14/368269 [patent_app_country] => US [patent_app_date] => 2012-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27121 [patent_no_of_claims] => 81 [patent_no_of_ind_claims] => 42 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14368269 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8830107 [patent_doc_number] => 20130131149 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-05-23 [patent_title] => 'METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF ANDROGEN RECEPTOR BY DOUBLE-STRANDED RNA' [patent_app_type] => utility [patent_app_number] => 13/723623 [patent_app_country] => US [patent_app_date] => 2012-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 45 [patent_figures_cnt] => 45 [patent_no_of_words] => 138722 [patent_no_of_claims] => 43 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13723623 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9844266 [patent_doc_number] => 08946183 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-02-03 [patent_title] => 'Compositions and methods for modulation of SMN2 splicing' [patent_app_type] => utility [patent_app_number] => 13/720474 [patent_app_country] => US [patent_app_date] => 2012-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13456 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13720474 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10920689 [patent_doc_number] => 20140323709 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-10-30 [patent_title] => 'OLIGONUCLEOTIDE AND THERAPEUTIC AGENT FOR HYPERLIPIDEMIA CONTAINING SAME AS ACTIVE INGREDIENT' [patent_app_type] => utility [patent_app_number] => 14/363315 [patent_app_country] => US [patent_app_date] => 2012-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 10570 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14363315 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11828981 [patent_doc_number] => 09725716 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-08-08 [patent_title] => 'Non-ionic, low osmolar contrast agents for delivery of antisense oligonucleotides and treatment of disease' [patent_app_type] => utility [patent_app_number] => 14/363670 [patent_app_country] => US [patent_app_date] => 2012-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 10 [patent_no_of_words] => 18219 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14363670 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9648637 [patent_doc_number] => 08802648 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-08-12 [patent_title] => 'Repressor on IFN-λ promoter and siRNA against ZEB1 and BLIMP-1 to increase IFN-λ gene activity' [patent_app_type] => utility [patent_app_number] => 13/693383 [patent_app_country] => US [patent_app_date] => 2012-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 28 [patent_no_of_words] => 16314 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13693383 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10162537 [patent_doc_number] => 09193754 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-11-24 [patent_title] => 'Formulations comprising antisense nucleotides to connexins' [patent_app_type] => utility [patent_app_number] => 13/681383 [patent_app_country] => US [patent_app_date] => 2012-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 19 [patent_no_of_words] => 11676 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13681383 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8830286 [patent_doc_number] => 20130131331 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-05-23 [patent_title] => 'CANCER-CELL-SPECIFIC CYTOSTATIC AGENT' [patent_app_type] => utility [patent_app_number] => 13/671118 [patent_app_country] => US [patent_app_date] => 2012-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 6855 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13671118 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11828986 [patent_doc_number] => 09725722 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-08-08 [patent_title] => 'Modulation of TMPRSS6 expression' [patent_app_type] => utility [patent_app_number] => 14/356863 [patent_app_country] => US [patent_app_date] => 2012-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23727 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14356863 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8815261 [patent_doc_number] => 20130116306 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-05-09 [patent_title] => 'SYSTEM FOR DELIVERING NUCLEIC ACIDS FOR SUPPRESSING TARGET GENE EXPRESSION BY UTILIZING ENDOGENOUS CHYLOMICRON' [patent_app_type] => utility [patent_app_number] => 13/668668 [patent_app_country] => US [patent_app_date] => 2012-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 12302 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13668668 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9756297 [patent_doc_number] => 20140286998 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-09-25 [patent_title] => 'Double-Stranded RNA For Immunostimulation' [patent_app_type] => utility [patent_app_number] => 14/355528 [patent_app_country] => US [patent_app_date] => 2012-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 5528 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14355528 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8892314 [patent_doc_number] => 20130165496 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-06-27 [patent_title] => 'COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF GCCR' [patent_app_type] => utility [patent_app_number] => 13/662263 [patent_app_country] => US [patent_app_date] => 2012-10-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 137572 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13662263 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9786210 [patent_doc_number] => 20140303030 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-10-09 [patent_title] => 'METHOD FOR IDENTIFYING APTAMERS' [patent_app_type] => utility [patent_app_number] => 14/354597 [patent_app_country] => US [patent_app_date] => 2012-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 15319 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14354597 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8866722 [patent_doc_number] => 20130150425 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-06-13 [patent_title] => 'ANTISENSE MODULATION OF GCCR EXPRESSION' [patent_app_type] => utility [patent_app_number] => 13/660885 [patent_app_country] => US [patent_app_date] => 2012-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40346 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13660885 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9691833 [patent_doc_number] => 08822427 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-09-02 [patent_title] => 'Methods and compositions to protect aquatic invertebrates from disease' [patent_app_type] => utility [patent_app_number] => 13/657898 [patent_app_country] => US [patent_app_date] => 2012-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 37 [patent_no_of_words] => 42938 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13657898 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9785690 [patent_doc_number] => 20140302510 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-10-09 [patent_title] => 'METHOD OF DIAGNOSIS, PROGNOSTIC OR TREATMENT OF NEURODEGENERATIVE DISEASES' [patent_app_type] => utility [patent_app_number] => 14/351616 [patent_app_country] => US [patent_app_date] => 2012-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 34 [patent_no_of_words] => 52008 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14351616 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8815260 [patent_doc_number] => 20130116305 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-05-09 [patent_title] => 'METHODS AND COMPOSITIONS FOR THE INHIBITION OF HIV-1 REPLICATION' [patent_app_type] => utility [patent_app_number] => 13/650526 [patent_app_country] => US [patent_app_date] => 2012-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 24998 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13650526 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9757453 [patent_doc_number] => 20140288155 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-09-25 [patent_title] => 'EXON SKIPPING THERAPY FOR DYSTROPHIC EPIDERMOLYSIS BULLOSA' [patent_app_type] => utility [patent_app_number] => 14/350921 [patent_app_country] => US [patent_app_date] => 2012-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 7324 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14350921 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9635529 [patent_doc_number] => 20140213639 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-07-31 [patent_title] => 'Optimization of Vectors for Effective Delivery and Expression of Genetic Content' [patent_app_type] => utility [patent_app_number] => 14/238870 [patent_app_country] => US [patent_app_date] => 2012-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 10369 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14238870 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8815257 [patent_doc_number] => 20130116301 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-05-09 [patent_title] => 'ANTISENSE MODULATION OF GCGR EXPRESSION' [patent_app_type] => utility [patent_app_number] => 13/623337 [patent_app_country] => US [patent_app_date] => 2012-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45155 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13623337 [rel_patent_id] =>[rel_patent_doc_number] =>)